P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses ; volume:6 ; number:3 ; day:22 ; month:10 ; year:2009 ; pages:1 ; date:10.2009
Retrovirology ; 6, Heft 3 (22.10.2009), 1, 10.2009
- Urheber
-
Wild, J.
- Beteiligte Personen und Organisationen
-
Köstler, J.
Bredl, S.
Böckl, K.
Kindsmüller, K.
Wagner, R.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-6-S3-P352
- URN
-
urn:nbn:de:1111-2016080711472
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wild, J.
- Köstler, J.
- Bredl, S.
- Böckl, K.
- Kindsmüller, K.
- Wagner, R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform
P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform
P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
P19-36. Preclinical study of CombiHIVvac vaccine
P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
P19-15. Synthesis of multivalent mimotopes as potential vaccine candidates
P19-30. GTU® as beneficial HIV DNA vaccine vector system
P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
P19-28. The V3 region of HIV-1: from NMR to vaccine design
HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform